retatrutide 2 months Effects of once-weekly subcutaneous on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials Lilly Prepares for Retatrutide FDA

In Phase 3 studies: Participants without diabetes taking orforglipron lost approximately 9% to 10% of body weight over roughly 36 to 40 weeks Participants with type 2 diabetes generally lost around 7% to 8% By comparison, Wegovy's landmark STEP trials reported approximately 14.9% average weight loss over 68 weeks

GLP-1 users are starting to feel the effects of stricter FDA rules for compounded semaglutide production

Thyroid Meds and PPIs: Managing the Morning "Traffic Jam" Both thyroid medications and proton pump inhibitors (PPIs, medications that significantly reduce stomach acid production) are taken first thing in the morning, 30 to 60 minutes before your first meal essentially, the same time as a GLP-1 pill

This brief discusses the current landscape of Medicaid GLP-1 coverage and examines recent trends in Medicaid prescriptions and gross spending on GLP-1s

"Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide"

Such acquisition of new function, termed moonlighting, is observed in many genes